Avantra Biosciences this week said that it will work with TGen Drug Development, or TD2, to test and develop applications for its Q400 Biomarker Workstation.
Avantra Biosciences this week said that it will work with TGen Drug Development, or TD2, to test and develop applications for its Q400 Biomarker Workstation.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.